OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating OHR-102 eye drops, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.